Co-Authors
This is a "connection" page, showing publications co-authored by JEFFREY N MYERS and MERRILL S KIES.
Connection Strength
0.825
-
Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234. Adv Radiat Oncol. 2022 Nov-Dec; 7(6):100989.
Score: 0.219
-
Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. Cancer Res. 2015 Apr 01; 75(7):1205-15.
Score: 0.132
-
Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival. Head Neck. 2013 Oct; 35(10):1454-60.
Score: 0.112
-
Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. Clin Cancer Res. 2022 Apr 20.
Score: 0.054
-
Editor's Note: Identification of Insulin-Like Growth Factor Binding Protein-3 as a Farnesyl Transferase Inhibitor SCH66336-Induced Negative Regulator of Angiogenesis in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2019 08 01; 25(15):4861.
Score: 0.045
-
Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer. Cancer Res. 2015 Apr 01; 75(7):1527-36.
Score: 0.033
-
Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol. 2014 Aug 10; 32(23):2486-95.
Score: 0.032
-
Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma. Arch Ophthalmol. 2012 Dec; 130(12):1608-11.
Score: 0.028
-
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013 Feb 20; 31(6):744-51.
Score: 0.028
-
Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther. 2010 Jun; 9(6):1755-63.
Score: 0.024
-
Implications of methylation patterns of cancer genes in salivary gland tumors. Clin Cancer Res. 2006 Dec 15; 12(24):7353-8.
Score: 0.019
-
Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2006 Sep 01; 24(25):4163-9.
Score: 0.018
-
Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clin Cancer Res. 2006 Jan 15; 12(2):653-61.
Score: 0.018
-
Differential expression of p63 isotypes (DeltaN and TA) in salivary gland neoplasms: biological and diagnostic implications. Hum Pathol. 2005 Jul; 36(7):821-7.
Score: 0.017
-
Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma? Cancer. 2004 Mar 15; 100(6):1171-8.
Score: 0.016
-
Outcomes in patients with adenoid cystic carcinoma of the lacrimal gland. Ophthalmic Plast Reconstr Surg. 2004 Jan; 20(1):22-6.
Score: 0.015
-
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer. 2002 Jul 15; 95(2):322-30.
Score: 0.014